Abstract

The field of pharmaceutical science is a dynamic landscape driven by the pursuit of enhanced drug formulations and improved therapeutic outcomes. One remarkable journey within this domain is the polymorphism odyssey of rivaroxaban, a distinguished anticoagulant inhibitor targeting blood coagulation factor Xa. Rivaroxaban plays a key role in the prevention and treatment of thromboembolic disorders, including myocardial infarction, stroke, and deep venous thromboses. Its intricate crystal structures and diverse solid-state forms, each imparting unique properties affecting solubility, bioavailability, and stability, illuminate the challenges, breakthroughs, and relentless pursuit of superior drug performance in the pharmaceutical development of rivaroxaban. This work not only reflects the scientific commitment to enhancing therapeutic efficacy but also underscores the dynamic interplay between chemical innovation and clinical application in drug development.

Keywords

rivaroxaban, crystal structures, patent innovation, commercial viability, synthesis, pharmaceutical science